42
Participants
Start Date
November 30, 2010
Primary Completion Date
February 28, 2019
Study Completion Date
February 28, 2019
Everolimus
Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)
Pasireotide
Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
Everolimus and Pasireotide
Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
University of Pittsburgh Cancer Institute, Pittsburgh
Emory University Hospital Midtown, Atlanta
Emory University Winship Cancer Institute, Atlanta
Collaborators (1)
Novartis
INDUSTRY
Emory University
OTHER